EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study

Waranaree Winayanuwattikun, Vasanop Vachiramon iD, Teerapong Rattananukrom, Pasita Palakornkitti, Ngamcherd Sitpahul

Toxins · 31.10.2023 · 15 (11) · 636

DOI: 10.3390/toxins15110636 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Toxins, online erschienen am 31.10.2023. Verfasst von Waranaree Winayanuwattikun und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand. Hauptthemen laut MEDLINE: Botulinum Toxins, Type A, Breast Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Subcutaneous mastectomies in transmen have been gaining popularity. However, post-operative scars are an inevitable consequence. Recently, Botulinum neurotoxin A (BoNT-A) has shown positive effects in scar prevention. The objective of this study is to investigate the effectiveness of BoNT-A in scar prevention.

Methods

Fifteen patients who had undergone subcutaneous mastectomy were included. At 14 days post-surgery, either incoBoNT-A or a placebo was injected into the scar on each side. The primary outcome assessment measured the scar’s severity using the Vancouver Scar Scale (VSS) and the Patient and Observer Scar Assessment Scale (POSAS). The secondary outcome assessment evaluated the scar’s color using a standard measurement device. Outcome assessments were conducted until 6 months post-surgery.

Results

There were significantly lower VSS scores in the BoNT-A group compared to the placebo at the end of the study (7.43 ± 0.26 vs. 8.82 ± 0.26, p < 0.001). The objective assessment revealed a statistically significant decrease in redness values in the BoNT-A group compared to the placebo at 3 and 6 months.

Conclusion

BoNT-A has demonstrated effectiveness in scar prevention by reducing the severity of postoperative scar formation and improving overall scar appearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Botulinum Toxins, Type ABreast NeoplasmsHumansFemaleCicatrixTreatment OutcomeProspective StudiesMastectomy

Stichwörter der Autor:innen

injectablesneuromodulatorsneurotoxinsurgical scars

Substanzen

Botulinum Toxins, Type A

Autor:innen und Institutionen

  • Division of Dermatology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.
  • Department of Plastic and Maxillofacial Surgery, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand.

ORCID-Profile: Vasanop Vachiramon

Zitieren

APA

Winayanuwattikun, W., Vachiramon, V., Rattananukrom, T., Palakornkitti, P., & Sitpahul, N. (2023). Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study. Toxins, 15(11), 636. https://doi.org/10.3390/toxins15110636

Vancouver

Winayanuwattikun W, Vachiramon V, Rattananukrom T, Palakornkitti P, Sitpahul N. Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study. Toxins. 2023;15(11):636. doi:10.3390/toxins15110636

BibTeX
@article{Winayanuwattikun2023,
  author = {Winayanuwattikun, Waranaree and Vachiramon, Vasanop and Rattananukrom, Teerapong and Palakornkitti, Pasita and Sitpahul, Ngamcherd},
  title = {Efficacy of Botulinum Toxin Type A for Prevention of Post-Mastectomy Scar in Transmen: A Prospective, Randomized Study},
  journal = {Toxins},
  year = {2023},
  volume = {15},
  number = {11},
  pages = {636},
  doi = {10.3390/toxins15110636}
}
Kostenlos starten →